Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class ITerminatedJan 2, 2019Phenylephrine HClLabeling: Label Error on Declared Strength: Label incorrectly lists concentration as "10 mcg per mL" rather than the correct concentration of "100 mcg per mL".Advanced Pharma Inc. · D-0347-2019Class IIITerminatedJan 2, 2019Temozolomide CapsulesFailed Dissolution SpecificationsAmerigen Pharmaceuticals Inc. · D-0345-2019Class IIITerminatedJan 2, 2019Temozolomide CapsulesFailed Dissolution SpecificationsAmerigen Pharmaceuticals Inc. · D-0344-2019Class IIITerminatedDec 26, 2018AbsoricaSubpotent Drug: Isotretinoin content results were lower than the specification limit obtained during routing product monitoring.Sun Pharmaceutical Industries, Inc. · D-1207-2019Class IITerminatedDec 26, 2018Nevirapine Extended Release TabletsFailed Dissolution Specifications.Cipla Limited · D-0382-2019Class ITerminatedDec 26, 2018Lubrisine eye dropsLack of Sterility Assurance and Incorrect/Undeclared excipient: Product was found to contain undeclared colloidal silverResults RNA, LLC · D-0360-2019Class ITerminatedDec 26, 2018Dyural-80 Injection KitLabeling: Not eslewhere classified - The kits include Sodium Chloride, USP, 0.9% which was recalled by the manufacturer due to the product insert incorrectly stating...Asclemed USA Inc. dba Enovachem · D-0354-2019Class ITerminatedDec 26, 2018Dyural-40 Injection KitLabeling: Not eslewhere classified - The kits include Sodium Chloride, USP, 0.9% which was recalled by the manufacturer due to the product insert incorrectly stating...Asclemed USA Inc. dba Enovachem · D-0353-2019Class IIITerminatedDec 26, 2018Aprepitant CapsulesShortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack.Glenmark Pharmaceuticals Inc., USA · D-0349-2019Class IIITerminatedDec 26, 2018NYSTATIN Oral SuspensionFailed Impurities/Degradation Specifications:Out of specification for impurities.VistaPharm, Inc. · D-0348-2019Class IITerminatedDec 26, 2018Human Chorionic Gonadotropin 3000 IULack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.Pharm D Solutions, LLC · D-0343-2019Class IIITerminatedDec 26, 2018Options Rx Anti-Oxidant Oil-Free SunscreeenSubpotent Drug:Out of specification for percentage of active pharmaceutical ingredients.CBI Laboratories, Inc. · D-0342-2019Class IIITerminatedDec 26, 2018Advanced Protection Sunscreen spf 30Subpotent Drug:Out of specification for percentage of active pharmaceutical ingredients.CBI Laboratories, Inc. · D-0341-2019Class IITerminatedDec 26, 2018Oxybutynin Chloride TabletsLabeling: Wrong bar codeKVK-Tech, Inc. · D-0340-2019Class IITerminatedDec 26, 2018LevoxylSuperpotent Drug.Pfizer Inc. · D-0339-2019Class IITerminatedDec 26, 2018Monsel'sSuperpotent Drug: contains higher levels of Iron than labeled.Gordon Laboratories · D-0338-2019Class IITerminatedDec 26, 2018Infants' IbuprofenSuperpotent Drug: recalled lots may have higher concentration of ibuprofen.Tris Pharma Inc. · D-0337-2019Class IITerminatedDec 26, 2018Infants' IbuprofenSuperpotent Drug: recalled lots may have higher concentration of ibuprofen.Tris Pharma Inc. · D-0336-2019Class IITerminatedDec 26, 2018infants* IBUPROFENSuperpotent Drug: recalled lots may have higher concentration of ibuprofen.Tris Pharma Inc. · D-0335-2019Class IITerminatedDec 26, 2018Fentanyl Citrate 2 mcg per mLSub-potentPharmedium Services, LLC · D-0334-2019Class IITerminatedDec 26, 2018Fentanyl Citrate 2 mcg per mLSub-potentPharmedium Services, LLC · D-0333-2019Class IITerminatedDec 26, 2018OmnipaqueDefective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for...GE Healthcare Inc. Life Sciences · D-0319-2019Class IITerminatedDec 26, 2018Estradiol TabletsPresence of foreign tablet/capsule: A single foreign tablet was found in pharmacy dispensed bottle of 30 Estradiol 2 mg tablets.Epic Pharma, LLC · D-0297-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0332-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0331-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0330-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0329-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0328-2019Class IIOngoingDec 19, 2018Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0327-2019Class IIOngoingDec 19, 2018Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0326-2019Class IIOngoingDec 19, 2018Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0325-2019Class IIOngoingDec 19, 2018Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0324-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0323-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0322-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0321-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0320-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0318-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0317-2019Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0316-2019Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0315-2019